Capricor Therapeutics, Inc. shares closed 58% higher at $6.65 on August 14 following an announcement that the FDA would review an amendment containing 24-month data for deramiocel, its experimental Duchenne muscular dystrophy treatment. The stock had risen as much as 94% intraday before retracing some gains. The move represented a partial recovery from earlier losses sustained after an advisory panel voted 9-3 that available evidence did not establish deramiocel’s effectiveness for Duchenne-related cardiomyopathy.
The company plans to submit 24-month open-label extension data focused on upper-limb function to support its regulatory application. The FDA indicated it would review this amendment and postpone its August 22 decision deadline upon receiving the submission. The HOPE-3 trial was statistically powered around upper-limb function as its primary endpoint, with cardiac measures designated as a key secondary endpoint. Some panelists viewed the upper-limb evidence more favorably than the cardiac case that prompted the formal negative vote.
Significant technical and regulatory challenges remain. The FDA staff and advisory panel raised concerns about analytical methodology changes, incomplete data, measurement uncertainty, and whether the study population adequately represented patients with cardiomyopathy. A critical dispute involves Capricor’s statistical analysis, which produced a p-value of 0.029 for the upper-limb endpoint using SAP 3.0 methodology, while the FDA’s prespecified analysis yielded p=0.24. The proposed 24-month evidence derives from an open-label extension rather than a randomized, placebo-controlled design, limiting its ability to demonstrate treatment efficacy through longer follow-up.
Capricor held $237.9 million in cash and marketable securities at June 30 and is moderating commercial spending while maintaining launch readiness. The company reported no first-half revenue and recorded $42.9 million in second-quarter operating expenses. Analysts note that FDA willingness to consider additional evidence reduced immediate rejection risk, but the stock rally has outpaced underlying regulatory certainty. Deramiocel maintains a potential approval pathway, though meaningful questions regarding statistical reliability and evidence quality remain unresolved.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI